Type:50 Tablets
Generic Name:Losartan Potassium
Manufacturer:Benham Pharmaceuticals Ltd.
Price:৳202.50
Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure, Hypertensive Patients with Left Ventricular Hypertrophy
May be taken with or without food.
Oral Hypertension Adult: 50 mg once daily, may increase to 100 mg/day as single dose or in 2 divided doses if needed. Patients w/ intravascular volume depletion: Initially, 25 mg once daily. Diabetic nephropathy in Type 2 diabetes mellitus Adult: Initially, 50 mg once daily, may increase to 100 mg once daily depending on BP response. Heart failure, Hypertension and Left Ventricular Hypertrophy, Stroke risk reduction of hypertensive or LVH patients: Adult: Initially, 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of Losartan should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response
Hypertension <6 years: Safety and efficacy not established Child: >6 yr 20-50 kg: Initially, 0.7 mg/kg. Max: 50 mg/day; >50 kg: Initially, 1.4 mg/kg. Max: 100 mg/day.
Renal impairment: CrCl <20 ml/min: Initially 25 mg once daily.
Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug. Concomitant use w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min). Severe hepatic impairment. Pregnancy.
Losartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.
Volume-depleted patients including patients on high-dose diuretics. Patients w/ bilateral renal artery stenosis , aortic or mitral stenosis. Renal and mild to moderate hepatic impairment. Lactation. Monitoring Parameters Monitor BP, electrolytes and renal function. Lactation: Unknown if excreted in milk; not recommended
>10% Fatigue (14%),Hypoglycemia (14%),Anemia (14%),Urinary tract infection (UTI) (13%),Chest pain (12%),Weakness (14%),Diarrhea (2-15%),Cough; incidence higher in previous cough related to angiotensin-converting enzyme (ACE) inhibitor therapy (3-11%) 1-10% Upper respiratory tract infection (8%),Hypotension (7%),Dizziness (4%),Cellulitis (7%),Gastritis (5%),Nausea (2%) Frequency Not Defined Angioedema,Edema/swelling,Hypotension in hypovolemic or diuretic-using patients,Asthenia,Headache,Malaise,Nausea,Abdominal pain,Hyperkalemia,Back pain,Worsening renal failure
Pregnancy Categories C (first trimester) and D (second and third trimesters).
May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes. Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
